EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial

Niccolo' Bertini iD, Giulio Francolini iD, Vanessa Di Cataldo, Pietro Garlatti, Michele Aquilano iD, Giulio Frosini, Olga Ruggieri, Laura Masi, Raffaela Doro, Mauro Loi, Pierluigi Bonomo iD, Daniela Greto iD und 6 weitere

Cancers · 23.06.2025 · 17 (13) · 2092

DOI: 10.3390/cancers17132092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 23.06.2025. Verfasst von Niccolo' Bertini und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose/Objectives: Salvage radiotherapy (SRT) after a radical prostatectomy is a curative approach for patients with biochemical recurrence (BR). However, outcomes are often less favorable when imaging reveals macroscopic local recurrence. In such cases, dose escalation through stereotactic salvage radiotherapy (SSRT) may offer improved disease control. The STARR trial (NCT05455736) is a prospective, multicenter study evaluating the efficacy and safety of SSRT in patients with macroscopic prostate bed recurrence. This interim analysis reports early findings from the initial patient cohort. Materials and Methods: Patients with BR (PSA > 0.2 ng/mL) post-prostatectomy and PET-confirmed macroscopic recurrence (PSMA or Choline PET, confirmed by MRI) were eligible. Treatment involved CyberKnife®-based SSRT delivering 35 Gy in five fractions to the visible lesion. Androgen deprivation therapy (ADT) was not permitted. Complete biochemical response (CBR) was defined as PSA < 0.2 ng/mL, and biochemical response (BR) as a ≥50% PSA reduction. Additional outcomes included biochemical, radiological, and ADT-free survival (bPFS, rPFS, aPFS).

Results

As of analysis, 51 patients were enrolled, with a median follow-up of 16 months (95% CI: 16–22). CBR and BR were achieved in 45.1% and 80.4% of patients, respectively. Events affecting bPFS, rPFS, and aPFS occurred in 12, 5, and 6 patients, with median values not yet reached. Toxicity was minimal, with two cases each of acute grade 2 GI and GU events, and one late grade 2 GI event. No grade ≥ 3 toxicities were reported.

Conclusion

Early data support SSRT as a safe and a promising option for macroscopic local recurrence, with encouraging response rates and minimal toxicity.

Schlagwörter

Stichwörter der Autor:innen

adjuvant therapyprostate cancerradical prostatectomy

Autor:innen und Institutionen

  • Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
  • Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.
  • CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, 50139 Florence, Italy.
  • Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, 50134 Florence, Italy.
  • Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, 50134 Florence, Italy.

ORCID-Profile: Niccolo' Bertini, Giulio Francolini, Michele Aquilano, Pierluigi Bonomo, Daniela Greto, Isacco Desideri, Gabriele Simontacchi, Icro Meattini, Riccardo Campi

Zitieren

APA

Bertini, N., Francolini, G., Di Cataldo, V., Garlatti, P., Aquilano, M., Frosini, G., Ruggieri, O., Masi, L., Doro, R., Loi, M., Bonomo, P., Greto, D., Desideri, I., Simontacchi, G., Meattini, I., Campi, R., Masieri, L., & Livi, L. (2025). Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial. Cancers, 17(13), 2092. https://doi.org/10.3390/cancers17132092

Vancouver

Bertini N, Francolini G, Di Cataldo V, Garlatti P, Aquilano M, Frosini G, et al. Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial. Cancers. 2025;17(13):2092. doi:10.3390/cancers17132092

BibTeX
@article{Bertini2025,
  author = {Bertini, Niccolo' and Francolini, Giulio and Di Cataldo, Vanessa and Garlatti, Pietro and Aquilano, Michele and Frosini, Giulio and Ruggieri, Olga and Masi, Laura and Doro, Raffaela and Loi, Mauro and Bonomo, Pierluigi and Greto, Daniela and Desideri, Isacco and Simontacchi, Gabriele and Meattini, Icro and Campi, Riccardo and Masieri, Lorenzo and Livi, Lorenzo},
  title = {Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {13},
  pages = {2092},
  doi = {10.3390/cancers17132092}
}
Kostenlos starten →